Agios Pharmaceuticals Inc
AGIO
Market Cap$1.58B
Close$
$-9.53
134.9% downside
Current Fair Value
134.9% downsideOvervalued by 134.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.58 Billion |
|---|---|
| Enterprise Value | $1.56 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $11.86 |
| Beta | 0.77 |
| Outstanding Shares | 57,459,195 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 2.36 |
|---|---|
| PEG | 24.83 |
| Price to Sales | - |
| Price to Book Ratio | 1.09 |
| Enterprise Value to Revenue | 42.04 |
| Enterprise Value to EBIT | -3.53 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Agios Pharmaceuticals Inc
536 employees
CEO: Jacqualyn Fouse Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation b...